JP2008535854A - 癌の診断、検出および処置におけるａｄａｍ１０ - Google Patents

癌の診断、検出および処置におけるａｄａｍ１０ Download PDF

Info

Publication number
JP2008535854A
JP2008535854A JP2008505601A JP2008505601A JP2008535854A JP 2008535854 A JP2008535854 A JP 2008535854A JP 2008505601 A JP2008505601 A JP 2008505601A JP 2008505601 A JP2008505601 A JP 2008505601A JP 2008535854 A JP2008535854 A JP 2008535854A
Authority
JP
Japan
Prior art keywords
cancer
antibody
adam10
cells
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008505601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535854A5 (enExample
Inventor
アルバート レイ，
アブダラ ファニディ，
ロバート ブーハー，
クリスティン チェ，
シエ スー，
グオイン ユー，
エドワード モウラー，
マイケル ロー，
Original Assignee
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド
サグレス ディスカバリー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド, サグレス ディスカバリー， インコーポレイテッド filed Critical ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド
Publication of JP2008535854A publication Critical patent/JP2008535854A/ja
Publication of JP2008535854A5 publication Critical patent/JP2008535854A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2008505601A 2005-04-07 2006-04-07 癌の診断、検出および処置におけるａｄａｍ１０ Pending JP2008535854A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66986205P 2005-04-07 2005-04-07
PCT/US2006/013156 WO2006110583A2 (en) 2005-04-07 2006-04-07 Adam10 in cancer diagnosis, detection and treatment

Publications (2)

Publication Number Publication Date
JP2008535854A true JP2008535854A (ja) 2008-09-04
JP2008535854A5 JP2008535854A5 (enExample) 2009-05-07

Family

ID=37087563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008505601A Pending JP2008535854A (ja) 2005-04-07 2006-04-07 癌の診断、検出および処置におけるａｄａｍ１０

Country Status (6)

Country Link
US (1) US20090297507A1 (enExample)
EP (1) EP1896580A2 (enExample)
JP (1) JP2008535854A (enExample)
AU (1) AU2006235260A1 (enExample)
CA (1) CA2604883A1 (enExample)
WO (1) WO2006110583A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101485163B1 (ko) 2012-02-21 2015-01-23 고려대학교 산학협력단 메탈로프로테이즈 ａｄａｍ１７에 의한 도파민성 신경세포로의 분화 조절 조성물
US20160040126A1 (en) * 2012-02-21 2016-02-11 Korea University Research And Business Foundation Regulation of differentiation into dopaminergic neurons by metalloprotease
MX2020004218A (es) 2017-10-02 2020-11-11 Verra Therapeutics Métodos y composiciones para inhibir las actividades biológicas de adam10.
US12247232B2 (en) 2018-01-31 2025-03-11 Verra Therapeutics, Inc. Methods and compositions for inhibiting ADAM 9 biological activities
CN113588940B (zh) * 2021-07-30 2023-05-12 菲鹏生物股份有限公司 一种提高间接标记灵敏度的方法和试剂盒
CN118987232A (zh) * 2024-08-08 2024-11-22 武汉科技大学 靶向cd30的car-t细胞与adam10抑制剂联合制备治疗cd30阳性淋巴瘤的药物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003237532B2 (en) * 2002-06-12 2009-07-30 Symphony Evolution, Inc. Human ADAM-10 inhibitors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5008003406; ＣＬＩＮＩＣＡＬ　＆　ＥＸＰＥＲＩＭＥＮＴＡＬ　ＭＥＴＡＳＴＡＳＩＳ　［ＯＮＬＩＮＥ］ Ｖ２１, 2004, Ｐ５９９-６６２ *
JPN6011055495; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｅｌｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．１６８，　Ｎｏ．４, 200502, ｐ．６３３-６４２ *
JPN6011055496; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃｅｌｌ　Ｂｉｏｌｏｇｙ Ｖｏｌ．１５８，　Ｎｏ．２, 2002, ｐ．２２１-２２６ *
JPN6011055497; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｉｍｍｕｎｏｌｏｇｙ Ｖｏｌ．１７２，　Ｎｏ．６, 2004, ｐ．３６７８-３６８５ *
JPN6011055498; 生化学辞典（第３版） , 1998, ｐ．８８１, 株式会社　東京化学同人 *
JPN6011055499; Ｌａｎｃｅｔ Ｖｏｌ．３６２，　Ｎｏ．９３８７, 2003, ｐ．８６９-８７５ *
JPN6011055500; Ｂｉｏｃｈｅｍｉｃａｌ　ａｎｄ　Ｂｉｏｐｈｙｓｉｃａｌ　Ｒｅｓｅａｒｃｈ　Ｃｏｍｍｕｎｉｃａｔｉｏｎｓ Ｖｏｌ．２３５，　Ｎｏ．２, 1997, ｐ．４３７-４４２ *
JPN7011003854; Ｔｈｅ　Ｊｏｕｒｎａｌ　ｏｆ　Ｂｉｏｌｏｇｉｃａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．２７９，　Ｎｏ．６, 2004, ｐ．４５４１-４５５０ *

Also Published As

Publication number Publication date
AU2006235260A1 (en) 2006-10-19
WO2006110583A2 (en) 2006-10-19
CA2604883A1 (en) 2006-10-19
EP1896580A2 (en) 2008-03-12
WO2006110583A3 (en) 2007-04-26
US20090297507A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
JP2008535853A (ja) 癌関連遺伝子
US20070237770A1 (en) Novel compositions and methods in cancer
JP2008535857A (ja) 癌の診断、検出および処置におけるｃａｃｎａ１ｅ
AU2004276821A1 (en) Novel therapeutic targets in cancer
AU2004213432A1 (en) Novel therapeutic targets in cancer
US7919246B2 (en) SEMA4D in cancer diagnosis, detection and treatment
US20070098728A1 (en) Novel compositions and methods in cancer
JP4942219B2 (ja) 癌の診断、検出および処置におけるｄｄｒ２
US20090297507A1 (en) ADAM10 in Cancer Diagnosis, Detection and Treatment
CA2563367A1 (en) Novel compositions and methods in cancer
EP2204376A2 (en) Novel therapeutic targets in cancer
US20090317391A1 (en) Cancer Related Genes (PTPE)
CA2572509A1 (en) Novel compositions and methods in cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120808

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205